DUPIXENT demonstrated safety data in asthma patients requiring OCS2

Adverse events occurring in ≥5% of patients in either group in VENTUREd

DUPIXENT 300 mg Q2W + SOC
(n=103) n (%)

Viral upper respiratory
tract infection

9 (9)

Bronchitis

7 (7)

Sinusitis

7 (7)

Influenza

3 (3)

Eosinophiliae

14 (14)

Injection site reactionf

9 (9)

≥1 measurement of blood
eosinophil count >3000 cells/μL

13 (13)

PLACEBO + SOC (n=107) n (%)

ADVERSE EVENT
Viral upper respiratory
tract infection

19 (18)

Bronchitis

6 (6)

Sinusitis

4 (4)

Influenza

6 (6)

Eosinophiliae

1 (1)

Injection site reactionf

4 (4)

≥1 measurement of blood
eosinophil count >3000 cells/μL

1 (1)

dAdverse events in this category were reported according to preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA), version 20.0.

eThe adverse event of eosinophilia in this table is a combination of the preferred items of eosinophil count increase (in 7% of the patients in the DUPIXENT group vs no patients in the placebo group) and eosinophilia (7% vs 1%).

fInjection site reaction is a high-level term in MedDRA.

  • The safety population (VENTURE) included all patients who received at least 1 dose or a partial dose
    of DUPIXENT or placebo; data were analyzed according to the regimen received

OCS, oral corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks;
SOC, standard of care.